enGene Therapeutics Inc. (ENGN) Form 8-K — Sep 8, 2026
enGene Therapeutics reported fiscal third quarter 2026 results (quarter ended July 31, 2026), posting a net loss attributable to common shareholders of $32.5 million, or $0.47 per share, compared with $29.0 million, or $0.57 per share, a year ago. Total operating expenses rose to $34.0 million from $29.9 million, as R&D fell $2.5 million on manufacturing timing while G&A increased $6.6 million, largely on workforce reduction-related costs.
Key figures
- Total Assets
- 288322000
- Cash Position
- 266320000
- Total Liabilities
- 58032000
- Ga Expense Q3 FY2026
- 13924000
- Rd Expense Q3 FY2026
- 20090000
- Ga Expense Change Yo Y
- +$6.6 million
- Rd Expense Change Yo Y
- -$2.5 million
- Shareholders Equity
- 230290000
- Interim Cr Rate Cohort1
- 54%
- Warrant Exercise Price
- 11.5
- Cash Prior Fiscal Year End
- 202258000
- Pivotal Cohort1 Patients
- 125
- Weighted Avg Shares Q3 FY2026
- 69734610
- Total Operating Expenses Q3 FY2025
- 29947000
- Total Operating Expenses Q3 FY2026
- 34014000
- Progression To Muscle Invasive Disease
- 3.2%
Price after filing
1 day: 0.0%7 days: -1.1%30 days: -4.1%
Close on the filing date to close N calendar days later (from $1.82). Historical, not a forecast.
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.